Anti-diabetic effect and mechanism of Kursi Wufarikun Ziyabit in L6 rat skeletal muscle cells

被引:8
作者
Edirs, Salamet [1 ,3 ]
Jiang, Lan [1 ,2 ]
Xin, XueLei [1 ,2 ]
Aisa, Haji Akber [1 ,2 ]
机构
[1] Chinese Acad Sci, Xinjiang Tech Inst Phys & Chem, Key Lab Plant Resources & Chem Arid Zone, 40-1 Beijing Rd, Urumqi 830011, Xinjiang, Peoples R China
[2] Chinese Acad Sci, Xinjiang Tech Inst Phys & Chem, State Key Lab Basis Xinjiang Indigenous Med Plant, 40-1 Beijing Rd, Urumqi 830011, Xinjiang, Peoples R China
[3] Univ Chinese Acad Sci, 19 A Yuquan Rd, Beijing 100049, Peoples R China
基金
中国科学院西部之光基金; 中国国家自然科学基金;
关键词
Type; 2; diabetes; Kursi Wufarikun Ziyabit; Anti-diabetic activity; Insulin signaling pathway; Endoplasmic reticulum stress; PI3K/AKT SIGNALING PATHWAY; UNFOLDED-PROTEIN RESPONSE; RETICULUM ER STRESS; GLUCOSE-TRANSPORT; INSULIN-RECEPTOR; DIABETIC-RATS; IN-VITRO; TRANSLOCATION; PHOSPHORYLATION; TRANSDUCTION;
D O I
10.1016/j.jphs.2018.06.011
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Kursi Wufarikun Ziyabit (KWZ) is a traditional prescription that used in folk tea drinking for its health care effect in treatment of type 2 diabetes mellitus (T2DM) in central Asia. However, the underlying mechanism of KWZ in T2DM has not been investigated extensively. This study designed to observe the effect of KWZ on glucose consumption and assess the molecular mechanism on associated proteins in insulin signaling and ER stress pathway in L6 rat skeletal muscle cells. The results showed that, KWZ exhibited proteins of PTP-1B and alpha-glycosidase inhibitory activity in vitro. No cytotoxicity of KWZ was found on L6 cell line. The best effect of glucose consumption of cells was shown at 6.25 mu g/mL after KWZ treatment for 12 h. Expression of PTP-1B protein was inhibited by KWZ in L6 moytubes. PI3K-dependent Akt phosphorylation was found to be activated by KWZ. Moreover, the insulin-mediated induction of IRS-1 and GSK-3 were also activated by KWZ. Western blot results indicated that KWZ significantly improved the levels of ER stress proteins, which reduced the expression of GRP78, enhanced the expression of the PERK, eIF2 alpha and XBP1s. The activation of PERK/eIF2 alpha was likely consequence of GRP78 inhibition, and this might be beneficial for improving the stability of ER and alleviating insulin resistance. These results suggest that KWZ might be serving as the potential drug for the prevention and treatment of T2DM. (c) 2018 The Authors. Production and hosting by Elsevier B.V. on behalf of Japanese Pharmacological Society.
引用
收藏
页码:212 / 219
页数:8
相关论文
共 50 条
[41]   PATHO-PHYSIOLOGY OF INSULIN-SECRETION IN NON-INSULIN-DEPENDENT DIABETES-MELLITUS [J].
WARD, WK ;
BEARD, JC ;
HALTER, JB ;
PFEIFER, MA ;
PORTE, D .
DIABETES CARE, 1984, 7 (05) :491-502
[42]  
Xu X., 2009, FLORA OF KAZAKH 4
[43]   PTP1B: a double agent in metabolism and oncogenesis [J].
Yip, Shu-Chin ;
Saha, Sayanti ;
Chernoff, Jonathan .
TRENDS IN BIOCHEMICAL SCIENCES, 2010, 35 (08) :442-449
[44]   XBP1 mRNA is induced by ATF6 and spliced by IRE1 in response to ER stress to produce a highly active transcription factor [J].
Yoshida, H ;
Matsui, T ;
Yamamoto, A ;
Okada, T ;
Mori, K .
CELL, 2001, 107 (07) :881-891
[45]   ER stress and diseases [J].
Yoshida, Hiderou .
FEBS JOURNAL, 2007, 274 (03) :630-658
[46]  
Yu N, 2017, PLOS ONE, V12
[47]   PTP1B regulates leptin signal transduction in vivo [J].
Zabolotny, JM ;
Bence-Hanulec, KK ;
Stricker-Krongrad, A ;
Haj, F ;
Wang, YP ;
Minokoshi, Y ;
Kim, YB ;
Elmquist, JK ;
Tartaglia, LA ;
Kahn, BB ;
Neel, BG .
DEVELOPMENTAL CELL, 2002, 2 (04) :489-495
[48]   The potential dual effects of sevoflurane on AKT/GSK3 beta signaling pathway [J].
Zhang, Lei ;
Zhang, Jie ;
Dong, Yuanlin ;
Swain, Celeste A. ;
Zhang, Yiying ;
Xie, Zhongcong .
MEDICAL GAS RESEARCH, 2014, 4
[49]   Berberine stimulates glucose transport through a mechanism distinct from insulin [J].
Zhou, Libin ;
Yang, Ying ;
Wang, Xiao ;
Liu, Shangquan ;
Shang, Wenbin ;
Yuan, Guoyue ;
Li, Fengying ;
Tang, Jinfeng ;
Chen, Mingdao ;
Chen, Jialun .
METABOLISM-CLINICAL AND EXPERIMENTAL, 2007, 56 (03) :405-412
[50]  
Zhu M., 2010, AVICENNA MED